当前位置: X-MOL 学术Adv. Mater. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
Advanced Materials ( IF 29.4 ) Pub Date : 2017-11-02 , DOI: 10.1002/adma.201703969
Ashley V. Kroll 1 , Ronnie H. Fang 1 , Yao Jiang 1 , Jiarong Zhou 1 , Xiaoli Wei 1 , Chun Lai Yu 1 , Jie Gao 1 , Brian T. Luk 1 , Diana Dehaini 1 , Weiwei Gao 1 , Liangfang Zhang 1
Affiliation  

Anticancer vaccines train the body's own immune system to recognize and eliminate malignant cells based on differential antigen expression. While conceptually attractive, clinical efficacy is lacking given several key challenges stemming from the similarities between cancerous and healthy tissue. Ideally, an effective vaccine formulation would deliver multiple tumor antigens in a fashion that potently stimulates endogenous immune responses against those antigens. Here, it is reported on the fabrication of a biomimetic, nanoparticulate anticancer vaccine that is capable of delivering autologously derived tumor antigen material together with a highly immunostimulatory adjuvant. The two major components, tumor antigens and adjuvant, are presented concurrently in a fashion that maximizes their ability to promote effective antigen presentation and activation of downstream immune processes. Ultimately, it is demonstrated that the formulation can elicit potent antitumor immune responses in vivo. When combined with additional immunotherapies such as checkpoint blockades, the nanovaccine demonstrates substantial therapeutic effect. Overall, the work represents the rational application of nanotechnology for immunoengineering and can provide a blueprint for the future development of personalized, autologous anticancer vaccines with broad applicability.

中文翻译:

癌细胞膜的纳米颗粒传递引发多抗原抗肿瘤免疫

抗癌疫苗训练人体自身的免疫系统,以基于差异性抗原表达来识别和消除恶性细胞。尽管从概念上讲吸引人,但由于癌性组织与健康组织之间的相似性带来了几个关键挑战,因此缺乏临床疗效。理想地,有效的疫苗制剂将以有效刺激针对那些抗原的内源性免疫应答的方式递送多种肿瘤抗原。在此,报道了仿生的纳米微粒抗癌疫苗的制备,该疫苗能够递送自体衍生的肿瘤抗原材料以及高度免疫刺激的佐剂。两个主要成分,肿瘤抗原和佐剂,以最大化其促进有效抗原呈递和激活下游免疫过程的能力的方式同时呈递“Aβ1”。最终,证明了该制剂可以在体内引起有效的抗肿瘤免疫应答。当与其他免疫疗法(如检查点封锁)组合使用时,纳米疫苗显示出实质性的治疗效果。总的来说,这项工作代表了纳米技术在免疫工程中的合理应用,并且可以为具有广泛适用性的个性化,自体抗癌疫苗的未来发展提供蓝图。纳米疫苗显示出实质性的治疗作用。总的来说,这项工作代表了纳米技术在免疫工程中的合理应用,并且可以为具有广泛适用性的个性化,自体抗癌疫苗的未来发展提供蓝图。纳米疫苗显示出实质性的治疗作用。总的来说,这项工作代表了纳米技术在免疫工程中的合理应用,并且可以为具有广泛适用性的个性化,自体抗癌疫苗的未来发展提供蓝图。
更新日期:2017-11-02
down
wechat
bug